$OGEN News

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

ORAGENICS PROVIDES INVESTOR UPDATE

Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002

Reported Earlier, Oragenics Receives Going Concern Audit Opinion In Annual Report For Fiscal Year Ended December 31, 2025

Reported Earlier, Oragenics Receives Going Concern Audit Opinion In Annual Report For Fiscal Year Ended December 31, 2025

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

ORAGENICS FILES ANNUAL REPORT ON FORM 10-K

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Oragenics Completes First Site Initiation Visit For Its Phase IIa Clinical Study Of ONP-002 In Australia

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

Oragenics Explores Acquisition Of Additional Assets In Central Nervous System Space; No Definitive Agreements Signed

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment

Oragenics previews targeted milestones for 2026